Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?
Harvard Bioscience shares fell to $0.40 in October 2025, down 84% year-over-year, after hitting a 52-week low of $0.28. Nasdaq granted a 180-day extension to regain $1 compliance, and the company is considering a reverse split. Q2 revenue dropped 12% to $20.5 million, but cash flow improved. Debt refinancing is required by December 2025, and John Duke became CEO in July after Jim Green’s retirement.
